Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Autologous Stem Cell Transplantation (ASCT)
Treatment for Multiple myeloma
Typical Dosage: High-dose Melphalan (e.g., 200 mg/m² IV) single dose
Effectiveness
90%
Safety Score
25%
Clinical Trials
144
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
High-dose Melphalan (e.g., 200 mg/m² IV) single dose
Time to Effect
3-6 months
Treatment Duration
Initial phase 1-2 months, then maintenance for years
Evidence Quality
HIGHConfidence Score
94%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$120,000
Side Effect Mgmt:$25,000
Total Annual:$150,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$176,471
Cost per Remission
$250,000
Comparison vs Conventional Chemotherapy without transplant
Cost Difference
+$70,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Autologous Stem Cell Transplantation (ASCT) Outcomes
for Multiple myeloma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+60%
Common Side Effects
Myelosuppression (severe neutropenia, thrombocytopenia)
+90%
Mucositis
+80%
Infections (bacterial, viral, fungal)
+60%
Fatigue
+80%
Nausea/Vomiting/Diarrhea
+60%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Autologous Stem Cell Transplantation (ASCT) in Multiple myeloma
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
NCT06963866NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Xuzhou, China
Started: May 1, 2025
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
NCT06463717RECRUITING
210 participants
OBSERVATIONAL
Hangzhou, China
Started: Dec 1, 2023
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380RECRUITINGPHASE1, PHASE2
20 participants
INTERVENTIONAL
Tianjin, China
Started: Jul 14, 2022
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Birmingham, United States +10 more
Started: Aug 8, 2025
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
NCT03562169RECRUITINGPHASE3
406 participants
INTERVENTIONAL
Aberdeen, United Kingdom +90 more
Started: Mar 20, 2017
CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
NCT07070934NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Started: Jul 15, 2025
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630ACTIVE NOT RECRUITING
69 participants
OBSERVATIONAL
Tampa, United States
Started: Apr 20, 2022
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
NCT07106710RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Tianjin, China
Started: Aug 10, 2025
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
NCT07106684RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Tianjin, China
Started: Aug 10, 2025
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT03346135ACTIVE NOT RECRUITINGPHASE2
31 participants
INTERVENTIONAL
Duarte, United States +1 more
Started: Jul 17, 2019
Completed Clinical Trials
4 completed trials for Autologous Stem Cell Transplantation (ASCT) in Multiple myeloma
A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
NCT01852799COMPLETEDPHASE2
18 participants
INTERVENTIONAL
Shanghai, China
Started: Dec 1, 2012
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
NCT03477539COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Jacksonville, United States
Started: Apr 9, 2018
Stem Cell Transplantation for Patients With Multiple Myeloma
NCT01526096COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Chicago, United States
Started: Jul 12, 2011
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
NCT01827137COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
New York, United States
Started: Apr 1, 2013
Showing 20 of 145 total trials